GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices [1][3] Company Overview - GeneDx Holdings Corp. is under scrutiny following a report by Grizzly Research alleging widespread fraud, claiming that the company's growth is artificially inflated through illegal practices targeting Medicaid and Medicare [3] - The report specifically mentions "code stacking" as a method used by GeneDx to bill insurance providers for services that do not meet required criteria [3] Stock Performance - Following the allegations, GeneDx's stock price dropped by $4.84, or 6.72%, closing at $67.18 per share on February 5, 2025 [3]